Link to the full text authored by Dr. Robert Malone regarding Cationic liposome-mediated RNA transfection
Europe PMC
You'll have to forgive my skepticism, but I really do smell something very fishy about this guy. I've tried and tried to find out more about his scientific successes, but other than what he appears to have written about himself, there just isn't much.
Let me point out that if, as he states repeatedly, he "invented" the mRNA technology, this would be a hugely significant feat, and it should have been written up everywhere. But it isn't.
Have a read of this
Wikepedia article on the development of mRNA vaccines. He is not mentioned, except in 3 quite marginal footnotes. In fact, he has no entry on Wikipedia at all. I did find a Reddit statement that he did not "invent" the technology, but contributed only a minor bit early on -- which the Wikipedia article seems to support.
Now, I did find a piece in the German Wikipedia on him. (why only German? Why not English?) And translated, it supports what I said above -- minor contributor, who shortly after his contribution, left the lab he was working in, started elsewhere and quit in a few months due to "personal differences," and then moved out of that area of science altogether.
Below is the beginning of the German Wiki entry, followed by the translation:
"Malone studierte Medizin an der Northwestern University mit dem Abschluss eines M.D., war Postdoktorand in klinischer Forschung an der Harvard University und erhielt seine Facharztausbildung in Pathologie an der University of California, Davis.[2] Als Doktorand am Salk Institute for Biological Studies in La Jolla war er einer der Hauptautoren und treibende Kraft einer Studie, in der erstmals beschrieben wurde, wie Proteinexpression in einer Fremdzelle über durch in Fettkügelchen (Liposomen) verpackte DNA bzw. RNA angestoßen werden kann, damals noch im Rahmen der Hoffnungen zur Gentherapie. Das gilt als erste wissenschaftliche Veröffentlichung zu den grundlegenden Prinzipien zum Beispiel von RNA-Impfstoffen, die bei der Covid-19-Pandemie 2020/21 erfolgreich waren.[3][4] Ko-Autoren der grundlegenden Arbeit von 1989 waren Philip Felgner und Inder Verma.[5] In einer Folgearbeit, die ursprünglich nur zur Kontrolle der Übertragung mittels Liposomen diente, wurde erstmals gezeigt, dass auch „nackte“ ungeschützte m-RNA, die direkt in die Muskelzellen von Mäusen injiziert wurde, Proteinexpression in Zellen über einige Tage auslösen können.[6][4] Die entscheidenden Patente (siehe Schriftenverzeichnis, daran beteiligt war auch Philip Felgner, später Leiter des Zentrums für Impfstoffentwicklung an der University of California, Irvine) verblieben bei seiner arbeitgebenden Firma, das sie später weiterverkaufte. Er war vom Salk-Institut an einen anderen Arbeitgeber gewechselt[7] und dort schon nach drei Monaten wegen persönlicher Differenzen ausgeschieden.[3] Malone selbst wechselte bald darauf das Forschungsgebiet und arbeitete nicht weiter in dieser Richtung.[3]
Zurzeit (2021) lebt er in Madison (Virginia) und leitet eine eigene Beraterfirma."
"Malone studied medicine at Northwestern University with an M.D., was a postdoctoral fellow in clinical research at Harvard University, and received his residency in pathology from the University of California, Davis. [2] As a doctoral student at the Salk Institute for Biological Studies in La Jolla, he was one of the main authors and driving force behind a study that described for the first time how protein expression in a foreign cell can be triggered by DNA or RNA packed in liposomes still in line with the hopes for gene therapy. This is considered to be the first scientific publication on the basic principles of, for example, RNA vaccines that were successful in the Covid-19 pandemic 2020/21. [3] [4] Co-authors of the basic paper from 1989 were Philip Felgner and Inder Verma. [5] In a follow-up study, which originally only served to control the transmission by means of liposomes, it was shown for the first time that "naked" unprotected m-RNA, which was injected directly into the muscle cells of mice, can trigger protein expression in cells over a period of several days. [6 ] [4] The decisive patents (see list of publications, also involved was Philip Felgner, later head of the Center for Vaccine Development at the University of California, Irvine) remained with his employer, which they later sold on. He moved from the Salk Institute to another employer [7] and left there after three months due to personal differences. [3] Malone himself changed the field of research soon after and did not work further in this direction. [3]
He currently (2021) lives in Madison (Virginia) and runs his own consulting company."
